IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Keith L. Black and Nagendra S. Ningaraj

Appln. No.

Continuation of 09/491,500

Filed

1 4

October 29, 2003

Examiner

Unassigned

Customer No.:

20786

Commissioner for Patents Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

October 29, 2003

Transmittal of Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

This Transmittal is accompanied by a fee of \$180.00, for filing an Information Disclosure. However, if the Examiner determines no fee is required, the Commissioner is authorized to credit any overpayments or charge any additional fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles, Esq.

Reg. No. 33,052

King & Spalding 191 Peachtree St. Atlanta, Georgia 30303 404-572-3541 404-572-5145 (fax)

FORI	M P	ro-1	449, 4	Adapted	ı

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY, DOCKET NO. 08143.105002		SERIAL NO.		FILING DATE October 29, 2003					
APPLICANT Keith L. Black and Nagendra S. Nings			garai		GROUP				
				U.S. PA	TENT DOCUM	ENTS	-		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	_	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,518,499	05/21/06	Agar			i i	·	
	AB	5,767,160 06/16/98 Kaeseme			eyer				
		OTHER R	REFERENC	CES (Inclu	ding Author, Titl	le, Date, Pert	inent Pag	es, Etc.)	
	AC				a channel activat RACT ONLY.	tion to hypox	ic cerebro	ovasodilation	does not involve NO,
	AD		Barna, M., et al., Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection, Virology, 223: 331-343 (1996).						
	AE		Becker, E.M., et al., The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rate platelets, J Cardiovasc Pharmacol, 35(3):390-7 (2000). ABSTRACT ONLY.						
	AF	1	Boje, K.M., Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis, Brain Research, 720:75-83 (1996).						
	AG	microvasculati	Brandt, L., et al., Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia, Journal of Cerebral Blood Flow and Metabolism, 3:44-50 (1983).						
	AH		Brioni, J.D., et al., Activators of soluble guanylate cyclase for treatment of male erectile dysfunction, International Journal of Impotence Research, 14:8-14 (2002).						
	AI		Bychkov, R., et al. Calicum-activated potassium channels and nitrate-induced vasodilation in human coronary arteries, J. Pharacol Exp. Therap., 285:293-8 (1998). ABSTRACT ONLY.						
	AJ		Chandran, S., et al., Nitric oxide: concepts, current perspectives and future therapeutic implications, Indian Journal of Pharmacology, 30:351-366 (1998).						
	AK		Chi, O.Z., et al. Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia, Pharmacologylogy, 48:367-373 (1994).						
	AL		Cloughesy, T.F., et al., <i>Pharmacological blood-brain barrier modification for selective drug delivery</i> , Journal of Neuro-Oncology, 26:125-132 (1995).						
	AM	Feelisch, M., 7 Pharmcol, 358	Feelisch, M., The use of nitric oxide donors in pharmacological studies, Naunyn-Schmiedeberg's Arch Pharmcol, 358:113-122 (1998).						
	AN.		Fukao, M., et al., Cyclic GMP-dependent protein kindase activates cloned BKCa channels expressed in mammalian cells by direct phophorylation at serine 1072, J Biol Chem, 274(16):10927-35 (1999).						
	ÃO		Fukumura, D., et al., Role of nitric oxide in angiogenesis and microcirculation in tumors, Cancer and Metastasis Reviews, 17:77-89 (1998).						
	AP	He, P., et al., c	He, P., et al., cGMP modulates basal and activated microvessel permeability independenty of [Ca2+]i, Am J Physiol, 274:H1865-74 (1998). ABSTRACT ONLY.						
	AQ	Herrera, G.M., et al., Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis, J Cardiovasc Pharmacol, 31:921-9 (1998). ABSTRACT ONLY							
EXAMINE	R	· · · · · · · · · · · · · · · · · · ·				ATE CONSID			
		nitial if reference consident					P 609; Dra	w line through	citation if not in

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO. SERIAL NO. 08143/105002			FILING DATE October 29, 2003			
APPLICANT			GROUI			
Keith L. Black an	d Nagendra S. Nir	ngaraj				
	ОТНЕР	REFERENCES ((Including Autho	ding Author, Title, Date, Pertinent Pages, Etc.)		
AR	Holschermann, H., et al., Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells, Am J Physiol, 272:H91-8 (1997). ABSTRACT ONLY.					
AS				by intracarotid infusion of papaverine in treatment of ournal, 111(8):751-753 (1998).		
AT		Hurst, R.D., et al., Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier, Journal of Cellular Physiology, 167:89-94 (1996).				
AU	Inamura, T., Neurologica	Inamura, T., et al., Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma, Neurological Research, 16:125-128 (1994).				
AV	Inamura, T.,	Inamura, T., et al., Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors, J Neurosurg, 81:752-758 (1994).				
AW	Janigro, D., 75:528-528		f blood-brain ba	rrier endothelial cells by nitric oxide, Circulation Research,		
AX		, et al., <i>Responses o</i> <u>Pharmacol</u> , 32: 695		and other isolated arteries to novel nitric oxide donors, <u>J</u> STRACT ONLY.		
AY	Koesling, D (1998).	., Modulators of sol	luble guanylyl cy	velase, Naunyn-Schmiedeberg's Arch Pharmacol, 358:123-126		
AZ	Liu, Y., et a	l., Repeated, short-i	term ischemia au a, Neurological I	agments bradykinin-mediated opening of the blood-tumor Research, 23:631-639 (2001).		
ВА		Lohse, M.J., et al., <i>Pharmacology of NO:cGMP signal transduction</i> , Naunyn-Schmiedeberg's Arch Pharmcol, 358:111-112 (1998).				
ВВ		Matskado, T., et al., Selective Increase in Blood Tumor Permeability by Calcium Antagonists in Transplanted Brain Tumors, Acta Neurochir, 60: 403-405 (1994).				
BC		Mayer, B., et al., Nitric oxide synthases: catalytic function and progress toward selective inhibition, Naunyn-Schmiedeberg's Arch Pharmcol, 358:127-133 (1998).				
BD		Mayhan, W.G., Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier, Brain Research, 743:70-76 (1996).				
BE	Mayhan, W. (1996).	Mayhan, W.G., et al., Glutamate-induced disruption of the blood-brain barrier in rats, Stroke, 27:965-970				
BF		Nakano, S., et al., Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide, Cancer Research, 56:4027-4031 (1996).				
BG	of Neurolog	Ningaraj, N.S., et al., <i>Role of ATP-sensitive K+ channels in blood-brain tumor barrier permeability</i> , <u>Congress of Neurological Surgeons Annual Meeting</u> , 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No. 4309, p. 215.				
EXAMINER	EXAMINER			DATE CONSIDERED		
		idered, whether or no de copy of this form v		formance with MPEP 609; Draw line through citation if not in cation to applicant.		

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO. 08143/105002		SERIAL NO.	FILING DATE October 29, 2003		
APPLICANT Keith L. Black and N	Nagendra S. Nin	garaj	GROUP		
	OTHER	REFERENCES (Inclu	ding Author, Title, Date, Pertinent Pages, Etc.)		
ВН	permeability	, Congress of Neurologic	ent K+ channels are a key regulatory of blood-brain tumor barrier cal Surgeons Annual Meeting, 50 th Anniversary Celebration, September nvention Center, San Antonio, Texas, ABSTRACT No.428, p. 219.		
BI	Ningaraj, N.S., et al., Nitric oxide donors increase blood-brain tumor barrier permeability via Kca channels, Society for Neuroscience, 30 th Annual Meeting, New Orleans, LA, November 4-9, 2000, 26 Part 1, p. 338, ABSTRACT No. 126.8.				
ВЈ	Pardrige, W., et al., Blood -brain barrier and new approaches to drug delivery, West J Med, 156:281-286 (1992).				
BK .	Robertson, B.E., et al., cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells, Am J Physiol, 265:C299-C303 (1993).				
BL	Sobey, C.G., et al., Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide, Br J Pharmacol, 126:1437-43 (1999). ABSTRACT ONLY.				
ВМ		et al., <i>Relaxant effects o</i> yy, 57:79-97 (1998). AB	f sodium nitroprusside and NONOates in rabbit basilar artery, STRACT ONLY.		
BN			exant effects of the NO donors sodium nitroprusside, DEA/NO and Gen Pharmacol, 32:75-59 (1999). ABSTRACT ONLY.		
ВО	Salom, J.B., et al., Relexant effects of sodium nitroprusside and NONates in goat middle cerebral artery: delayed impairment of global ischemia-reperfusion, Nitric Oxide, 3:85-93 (1999). ABSTRACT ONLY.				
BP	Shukla, A., et al., Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain, Experientia, 52:136-140 (1996).				
BQ	Smolenski, A., et al., Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects, Naunyn-Schmiedeberg's Arch Pharmacol, 358:134-138.				
BR	Sugita, M., et al., Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability in brain tumors, Cancer Research, 58:914-920 (1998).				
BS	Takayasu, M., et al., Effects of calcium antagonists on intracerebral penetrating arteriolesi in rats, <u>J. Neurosurg</u> , 69:104-109 (1988).				
BT	Uchida, M., et al., Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykinin-mediated blood-brain tumor varrier permeability increase, Neurological Research, 24:739-745				
EXAMINER			DATE CONSIDERED		
EVALUED. L. C.			: . :		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET N 08143/105002	SERIAL NO. FILING DATE October 29, 2003				
APPLICANT Keith L. Black	GROUP nd Nagendra S. Ningaraj				
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
BU	BU Uchida, M., et al., Cyclic GMP-dependent blood-brain tumor barrier permeability is not mediated by cyclic GMP-dependent protein kinase, Congress of Neurological Surgeons Annual Meeting, 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention center, San Antonio, Texas, ABSTR No. 440, p. 220.				
BV	Vodovotz, Y., et al., Regulation of transforming growth factor beta 1 by nitric oxide, Cancer Res, 59:2142-9 (1999). ABSTRACT ONLY.				
BW	Yukabu, M.A., Hematoma-induced enhanced cerebral vasoconstriction to leukotriene C4 and endothelin-1 piglets: role of prostanoids, Pediatr Res, 38:119-23 (1995). ABSTRACT ONLY.				
ВХ	Tocris Web Page, http://www.tocris.com/cat/nodonorstxt.html No Donors/Precursors, pp.1-2, Downloaded 5/31/00.				
BY	Sigma-Aldrich Web page, http://vsearch.sial.com/search 97cgi/s97-cgi, p.1, downloaded 5/31/00.				
EXAMINER	DATE CONSIDERED				
EXAMINER:	itial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.